Overcoming the Challenges of Multi-Country Registry Harmonization

As pharmaceutical companies expand global real-world evidence (RWE) efforts, the need for harmonized multi-country registries has never been greater. These registries enable data pooling across populations, improve generalizability, and support regulatory decisions across regions. However, harmonizing registry data and operations across multiple countries presents significant challenges. This guide offers practical strategies to overcome these hurdles, helping pharma professionals design and manage globally consistent, compliant, and effective registries.

Why Harmonization Matters in Global Registries:

Multi-country registries are essential for:

• Studying rare diseases where national populations are too small
• Comparing treatment patterns across regions
• Fulfilling regulatory requirements in diverse jurisdictions
• Generating robust RWE for global market access

However, achieving meaningful comparisons across countries demands harmonized protocols, data standards, and ethical practices. Misalignment in these areas can compromise scientific integrity and compliance with pharma regulatory compliance.

Challenge 1: Regulatory and Legal Diversity

Each country has its own legal framework governing data privacy, patient consent, and registry oversight. Examples include:

• GDPR (EU) with strict rules on cross-border data transfer
• HIPAA (USA) with healthcare-specific data protections
• China’s Personal Information Protection Law (PIPL)
• Local ethics committee requirements in Latin America, Africa, and Asia

Solution: Conduct early regulatory mapping, establish a master protocol with localized appendices, and use region-specific consent forms as per pharmaceutical SOP guidelines.

Challenge 2: Inconsistent Data Standards and Terminologies

Registries may use different:

• Coding systems (ICD-10 vs SNOMED CT)
• Laboratory units and reference ranges
• Outcome definitions (e.g., response criteria in oncology)
• Data formats (e.g., date conventions, decimal separators)

Solution: Define a Common Data Model (CDM) upfront, with mapping and conversion rules. Use global standards like HL7 FHIR, CDISC, and MedDRA, validated under CSV validation protocol.

Challenge 3: Multilingual Operations and Data Collection

Collecting data in multiple languages poses risks of mistranslation, inconsistent interpretations, and data entry errors. This affects:

• Patient-reported outcomes
• Site staff documentation
• Training materials and SOPs

Solution: Use standardized, validated translations of forms and instruments. Implement ePRO systems with built-in language toggles and audit trails aligned with GMP quality control standards.

Challenge 4: Ethical Review Variability

Ethical approval processes differ significantly. Some countries require:

• National central ethics board approval
• Institutional/local IRB approvals
• Health ministry clearances

Solution: Create a central ethics strategy and collaborate with in-country experts to manage submissions and approvals. Use region-specific templates and regulatory calendars.

Challenge 5: Infrastructure and Technology Gaps

In some regions, technology infrastructure is limited, affecting:

• Internet connectivity for electronic data capture
• Access to validated software platforms
• Availability of trained IT support staff

Solution: Provide offline data collection modules with batch upload capabilities. Host training webinars and help desks. Use lightweight, cloud-based systems validated through a Stability Studies-compliant architecture.

Challenge 6: Governance and Decision-Making Conflicts

In multi-country collaborations, disagreements may arise over:

• Data ownership and access rights
• Authorship and publication plans
• Data sharing with third parties

Solution: Establish a global governance board with defined roles, rotating leadership, and conflict resolution mechanisms. Publish a transparent data access and publication policy.

Challenge 7: Site Training and Consistency

Sites may vary in:

• Understanding registry protocols
• Experience with observational studies
• Resources for long-term data collection

Solution: Deploy standardized training modules in local languages, use e-learning platforms, and perform site readiness assessments. Monitor compliance through centralized dashboards and routine audits.

Best Practices for Harmonization:

• Develop a Global Master Protocol: Supplement with country-specific appendices
• Use Modular Data Architecture: Allow for optional fields and local extensions
• Implement Centralized Data Cleaning: Use harmonized edit checks and reconciliation tools
• Apply Risk-Based Monitoring: Focus QA resources on high-risk regions or data domains
• Standardize SOPs: Across all regions and partners for registry data handling

Real-World Example: Oncology Registry in APAC and EU

A multi-country registry in lung cancer spanned 12 countries across Asia and Europe. Challenges included:

• Differing AE reporting regulations
• Language translation inconsistencies in PRO tools
• Varying ethical approval timelines (from 2 weeks to 6 months)

By deploying eConsent solutions, modular CRFs, and localized SOPs, the registry achieved over 90% data harmonization and supported EMA and TGA post-marketing safety updates.

Conclusion:

Multi-country registry harmonization is a complex but achievable goal. With strategic planning, global-standard data models, centralized governance, and flexible tools, pharmaceutical organizations can overcome operational and regulatory challenges. As global demand for real-world data increases, well-harmonized registries will be essential in driving evidence-based healthcare decisions across borders.